About CeleCor Therapeutics
CeleCor Therapeutics is a company based in San Diego (United States) founded in 2017 by Barry S Coller, Andreas Ritzi, and Robert S Hillman.. CeleCor Therapeutics has raised $46.5 million across 2 funding rounds. CeleCor Therapeutics offers products and services including Zalunfiban. CeleCor Therapeutics operates in a competitive market with competitors including Acticor Biotech, Anthos Therapeutics, Basking Biosciences, 4TEEN4 Pharmaceuticals and AptaTargets, among others.
- Headquarter San Diego, United States
- Founders Barry S Coller, Andreas Ritzi, Robert S Hillman
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$46.5 M (USD)
in 2 rounds
-
Latest Funding Round
$45.5 M (USD), Series A
Feb 23, 2022
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CeleCor Therapeutics
CeleCor Therapeutics offers a comprehensive portfolio of products and services, including Zalunfiban. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides rapid platelet inhibition for heart attack treatment.
Unlock access to complete
Unlock access to complete
Funding Insights of CeleCor Therapeutics
CeleCor Therapeutics has successfully raised a total of $46.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $45.5 million completed in February 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $45.5M
-
First Round
First Round
(10 May 2021)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2022 | Amount | Series A - CeleCor Therapeutics | Valuation |
investors |
|
| May, 2021 | Amount | Seed - CeleCor Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by CeleCor Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CeleCor Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Celecor Therapeutics Comparisons
Competitors of CeleCor Therapeutics
CeleCor Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Acticor Biotech, Anthos Therapeutics, Basking Biosciences, 4TEEN4 Pharmaceuticals and AptaTargets, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for ischemic stroke treatment using monoclonal antibodies.
|
|
| domain | founded_year | HQ Location |
Novel anticoagulants for thrombosis treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for ischemic stroke treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics and diagnostics for cardiovascular diseases are developed.
|
|
| domain | founded_year | HQ Location |
Provider of therapeutic solutions for ischemic diseases
|
|
| domain | founded_year | HQ Location |
Peptide drugs for cardiovascular disorders are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Celecor Therapeutics
Frequently Asked Questions about CeleCor Therapeutics
When was CeleCor Therapeutics founded?
CeleCor Therapeutics was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Where is CeleCor Therapeutics located?
CeleCor Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of CeleCor Therapeutics?
Robert S Hillman is the current CEO of CeleCor Therapeutics. They have also founded this company.
Is CeleCor Therapeutics a funded company?
CeleCor Therapeutics is a funded company, having raised a total of $46.5M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on May 10, 2021.
What does CeleCor Therapeutics do?
CeleCor Therapeutics was founded in 2017 and is based in San Diego, United States. Focus is placed on biotechnology for cardiovascular therapeutics, where a proof-of-concept subcutaneous injectable is developed to address myocardial infarction. The approach targets platelet-mediated thrombosis via RUC-4, a small molecule inhibitor of the GPIIbIIIa receptor, aiming to prevent coronary artery closure. Operations center on drug development for heart attack intervention.
Who are the top competitors of CeleCor Therapeutics?
CeleCor Therapeutics's top competitors include Anthos Therapeutics, Acticor Biotech and 4TEEN4 Pharmaceuticals.
What products or services does CeleCor Therapeutics offer?
CeleCor Therapeutics offers Zalunfiban.